Get started
Author

Ralf Lutterbuese

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
2011 · Max S. Topp, Peter Kufer, et al. · Journal of Clinical Oncology · 914
PDF
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
2005 · Klaus Brischwein, Bernd Schlereth, et al. · Molecular Immunology · 260
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
2010 · Ralf Lutterbuese, Tobias Raum, et al. · Proceedings of the National Academy of Sciences · 166
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
2012 · Matthias Friedrich, Tobias Raum, et al. · Molecular Cancer Therapeutics · 145
Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct
2005 · Bernd Schlereth, Iduna Fichtner, et al. · Cancer Research · 134
Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
2008 · Maria Amann, Klaus Brischwein, et al. · Cancer Research · 88
Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2007 · Scott A. Hammond, Ralf Lutterbuese, et al. · Cancer Research · 82
PDF
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
2008 · Sandrine d’Argouges, Sandra Wissing, et al. · Leukemia Research · 80
Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
2009 · Ralf Lutterbuese, Tobias Raum, et al. · Journal of Immunotherapy · 78
Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release
2009 · Maria Amann, Sandrine dÁrgouges, et al. · Journal of Immunotherapy · 64
Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing
2017 · Tara L. Arvedson, Mercedesz Balazs, et al. · Cancer Research · 30
Therapeutic window of MuS110, a single-chain antibody construct bispecific for EpCAM (CD326) and CD3
2007 · Patrick A. Baeuerle, Maria Amann, et al. · Molecular Cancer Therapeutics · 3
Abstract 585: Assessing ENPP3 as a renal cancer target for bispecific T-cell engager (BiTE) therapy
2016 · Olivier Nolan-Stevaux, Flordeliza Fajardo, et al. · Cancer Research · 2
Abstract 3630: Preclinical evaluation of a BiTE® antibody construct with extended half-life that targets the tumor differentiation marker mesothelin
2017 · Alexander Sternjak, Fei Lee, et al. · Cancer Research · 1
Abstract 4561: Preclinical characterization of MT112/BAY 2010112, a novel PSMA/CD3-bispecific BiTE antibody for the treatment of prostate cancer
2011 · Ralf Lutterbuese, Matthias Friedrich, et al. · Cancer Research · 1
Data from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Supplementary Video 4E and F from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Supplementary Video 4J from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Supplementary Video 4C and D from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Supplementary Video 4L from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Supplementary Video 4K from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Supplementary Video 4G and H from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Supplementary Video 4A and B from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Supplementary Video 4I from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Data from Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
2023 · Scott A. Hammond, Ralf Lutterbuese, et al.
Works count: 29
Citation count: 2,048
H-index: 11
I10-index: 11
Year
Topic
Type